Raseglurant

Raseglurant (INN; development code ADX-10059) is a negative allosteric modulator of the mGlu₅ receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.^[1][2][3] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.^[3][4][5]

Raseglurant

Clinical data
ATC code	None
Identifiers
IUPAC name 2-[(3-Fluorophenyl)ethynyl]-4,6-dimethyl-3-pyridinamine
CAS Number	757950-09-7
PubChem CID	10331863
ChemSpider	8507323
UNII	66UCJ8Z8L1
CompTox Dashboard (EPA)	DTXSID40226707
Chemical and physical data
Formula	C15H13FN2
Molar mass	240.281 g·mol−1
3D model (JSmol)	Interactive image
SMILES Fc2cccc(C#Cc1nc(cc(c1N)C)C)c2
InChI InChI=1S/C15H13FN2/c1-10-8-11(2)18-14(15(10)17)7-6-12-4-3-5-13(16)9-12/h3-5,8-9H,17H2,1-2H3 Key:MEDCLNYIYBERKO-UHFFFAOYSA-N

See also

• Basimglurant
• Dipraglurant
• Fenobam
• Mavoglurant